Cargando…

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice

BACKGROUND: Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin) for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will survive long term. Paediatricians successfully reduce toxicities by using lower bleomycin doses and substituting carboplatin for...

Descripción completa

Detalles Bibliográficos
Autores principales: Newton, C., Murali, K., Ahmad, A., Hockings, H., Graham, R., Liberale, V., Sarker, S.-J., Ledermann, J., Berney, D.M., Shamash, J., Banerjee, S., Stoneham, S., Lockley, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522056/
https://www.ncbi.nlm.nih.gov/pubmed/30954883
http://dx.doi.org/10.1016/j.ejca.2019.03.001
_version_ 1783419069015261184
author Newton, C.
Murali, K.
Ahmad, A.
Hockings, H.
Graham, R.
Liberale, V.
Sarker, S.-J.
Ledermann, J.
Berney, D.M.
Shamash, J.
Banerjee, S.
Stoneham, S.
Lockley, M.
author_facet Newton, C.
Murali, K.
Ahmad, A.
Hockings, H.
Graham, R.
Liberale, V.
Sarker, S.-J.
Ledermann, J.
Berney, D.M.
Shamash, J.
Banerjee, S.
Stoneham, S.
Lockley, M.
author_sort Newton, C.
collection PubMed
description BACKGROUND: Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin) for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will survive long term. Paediatricians successfully reduce toxicities by using lower bleomycin doses and substituting carboplatin for cisplatin, while testicular and paediatric immature teratomas (ITs) are safely managed with surgery alone. AIM: The aim was to determine whether reduced-toxicity treatment could rationally be extended to patients older than 18 years. METHODS: Multicentre cohort study was carried out in four large UK cancer centres over 12 years. RESULTS: One hundred thirty-eight patients were enrolled. Overall survival was 93%, and event-free survival (EFS) was 72%. Neoadjuvant/adjuvant chemotherapy (82% BEP) caused 27 potentially chronic toxicities, and one patient subsequently died from acute lymphoblastic leukaemia. There was no difference in histology, stage or grade in patients ≤/>18 years, and EFS was not different in these age groups (≤18:28% and >18:28%; log-rank P = 0.96). Histological subtype powerfully predicted EFS (log-rank P = 4.9 × 10(−7)). Neoadjuvant/adjuvant chemotherapy reduced future relapse/progression in dysgerminoma (n = 37, chemo:0% vs. no chemo:20%), yolk sac tumour (n = 23, 26.3% vs.75%) and mixed germ cell tumour (n = 32, 40%vs.70%) but not in IT (n = 42, 33% vs.15%). Additionally, we observed no radiological responses to chemotherapy in ITs, pathological IT grade did not predict EFS (univariate hazard ratio 0.82, 95% confidence interval: 0.57–1.19, P = 0.94) and there were no deaths in this subtype. CONCLUSION: Survival was excellent but chemotherapy toxicities were severe, implying significant overtreatment. Our data support the extension of reduced-toxicity, paediatric regimens to adults. Our practice-changing findings that IT was chemotherapy resistant and pathological grade uninformative strongly endorse exclusive surgical management of ovarian ITs at all ages.
format Online
Article
Text
id pubmed-6522056
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier Science Ltd
record_format MEDLINE/PubMed
spelling pubmed-65220562019-05-24 A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice Newton, C. Murali, K. Ahmad, A. Hockings, H. Graham, R. Liberale, V. Sarker, S.-J. Ledermann, J. Berney, D.M. Shamash, J. Banerjee, S. Stoneham, S. Lockley, M. Eur J Cancer Article BACKGROUND: Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin) for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will survive long term. Paediatricians successfully reduce toxicities by using lower bleomycin doses and substituting carboplatin for cisplatin, while testicular and paediatric immature teratomas (ITs) are safely managed with surgery alone. AIM: The aim was to determine whether reduced-toxicity treatment could rationally be extended to patients older than 18 years. METHODS: Multicentre cohort study was carried out in four large UK cancer centres over 12 years. RESULTS: One hundred thirty-eight patients were enrolled. Overall survival was 93%, and event-free survival (EFS) was 72%. Neoadjuvant/adjuvant chemotherapy (82% BEP) caused 27 potentially chronic toxicities, and one patient subsequently died from acute lymphoblastic leukaemia. There was no difference in histology, stage or grade in patients ≤/>18 years, and EFS was not different in these age groups (≤18:28% and >18:28%; log-rank P = 0.96). Histological subtype powerfully predicted EFS (log-rank P = 4.9 × 10(−7)). Neoadjuvant/adjuvant chemotherapy reduced future relapse/progression in dysgerminoma (n = 37, chemo:0% vs. no chemo:20%), yolk sac tumour (n = 23, 26.3% vs.75%) and mixed germ cell tumour (n = 32, 40%vs.70%) but not in IT (n = 42, 33% vs.15%). Additionally, we observed no radiological responses to chemotherapy in ITs, pathological IT grade did not predict EFS (univariate hazard ratio 0.82, 95% confidence interval: 0.57–1.19, P = 0.94) and there were no deaths in this subtype. CONCLUSION: Survival was excellent but chemotherapy toxicities were severe, implying significant overtreatment. Our data support the extension of reduced-toxicity, paediatric regimens to adults. Our practice-changing findings that IT was chemotherapy resistant and pathological grade uninformative strongly endorse exclusive surgical management of ovarian ITs at all ages. Elsevier Science Ltd 2019-05 /pmc/articles/PMC6522056/ /pubmed/30954883 http://dx.doi.org/10.1016/j.ejca.2019.03.001 Text en © 2019 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Newton, C.
Murali, K.
Ahmad, A.
Hockings, H.
Graham, R.
Liberale, V.
Sarker, S.-J.
Ledermann, J.
Berney, D.M.
Shamash, J.
Banerjee, S.
Stoneham, S.
Lockley, M.
A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
title A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
title_full A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
title_fullStr A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
title_full_unstemmed A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
title_short A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
title_sort multicentre retrospective cohort study of ovarian germ cell tumours: evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522056/
https://www.ncbi.nlm.nih.gov/pubmed/30954883
http://dx.doi.org/10.1016/j.ejca.2019.03.001
work_keys_str_mv AT newtonc amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT muralik amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT ahmada amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT hockingsh amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT grahamr amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT liberalev amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT sarkersj amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT ledermannj amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT berneydm amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT shamashj amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT banerjees amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT stonehams amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT lockleym amulticentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT newtonc multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT muralik multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT ahmada multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT hockingsh multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT grahamr multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT liberalev multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT sarkersj multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT ledermannj multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT berneydm multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT shamashj multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT banerjees multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT stonehams multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice
AT lockleym multicentreretrospectivecohortstudyofovariangermcelltumoursevidenceforchemotherapydeescalationandalignmentofpaediatricandadultpractice